SHAWNEE, Kan.--(BUSINESS WIRE)--Jul 21, 2025--PBI-Gordon Companies, Inc. the parent company of TriviumVet, which holds sole conditional new animal drug approval from the FDA for Felycin ® -CA1 (sirolimus delayed-release tablets) under its affiliated brand company Pegasus, through its outside counsel issued a cease-and-desist demand letter to Petspan for falsely promoting a compounded version of rapamycin (synonymous with sirolimus) for the treatment and management of clinical hypertrophic cardiomyopathy (HCM) in cats. Petspan’s evaluation and prescribing practices do not comply with established veterinary practice principles and places the health and wellbeing of cats in jeopardy.Felycin-CA1 is the first and only drug to receive FDA conditional approval for management of ventricular hypertrophy with subclinical HCM in cats. It is also the only conditionally approved drug for which treatment claims are permitted based on studies that were conducted by or on behalf of the holder of the cNADA, TriviumVet.